Components in ERS signaling implicated in OC
| Molecule | Expression | Effects | Reference |
|---|---|---|---|
| ARID1A | Mutated in more than 50% of OCCC | Defining the IRE1a-XBP1 axis of the ERS response as a targetable vulnerability for ARID1A-mutant OCCC | 45 |
| ANKRD1 | Up-regulated in OC cells (vs. normal control) | Inducing platinum resistance | 48 |
| AGTR1 | Up-regulated in OC tissues (vs. normal tissues) | Correlating with poor outcomes and increasing lipid desaturation via SCD1 upregulation, thus ultimately decreasing ERS in multicellular spheroids | 55 |
| CARM1 | Up-regulated in approximately 20% of HGSOC | Hypersensitivity to inhibition of the IRE1α/XBP1s pathway, alone or in combination with immune checkpoint blockade | 44 |
| GRP78 | Up-regulated in OC tissues (vs. normal tissues) | Correlating with worse patient survival | 41 |
| GRP78 | Weak in cisplatin-sensitive OC cells | Mediating cisplatin-induced senescence | 24 |
| PDI | Up-regulated in OC tissues (vs. normal tissues) | Correlating with poorer patient survival | 41 |
| p62 | Up-regulated in cisplatin-resistant OC cells (vs. cisplatin-sensitive control) | Preventing ERS-induced apoptosis, and leading to cisplatin-resistance | 50 |
| PHLDA1 | Up-regulated in OC tissues (vs. normal tissues) | Correlating with poorer patient survival; modulating cell apoptosis via the ERS pathway | 49 |
| ROR2 | Down-regulated in HGSOC tissues (vs. normal tissues) | Association with HGSOC development and progression; overexpression of ROR2 induces cell apoptosis via IRE1α/JNK/CHOP pathway activation | 54 |
| Twist | Up-regulated in cisplatin-resistant OC cells (vs. cisplatin-sensitive control) | Association with cisplatin-resistance and ERS induction, thus leading to initiation of mitochondrial-mediated cell death | 51 |
| TUSC3 | Often lost in epithelial cancers | Association with poor prognosis; loss of TUSC3 alters the molecular response to ERS and induces hallmarks of epithelial-to-mesenchymal transition in OC cells | 42 |
| UCHL1 | Up-regulated in HGSOC tissues (vs. normal tissues) | Correlating with poor patient survival; UCHL1 inhibition attenuates mTORC1 activity and induces a terminal ERS response | 53 |
| WWOX | Frequently lost in several cancers | Mediating the sensitivity of OC cells to paclitaxel via modulation of the ERS response | 52 |
| XBP1 | Up-regulated in T cells | Decreasing intra-tumoral T cell infiltration and impairing anti-tumor capability | 47 |
| XBP1 | Up-regulated in dendritic cells | Driving OC progression by blunting anti-tumor immunity | 46 |
| XBP1 | Up-regulated in OC cells | Promoting cell proliferation and decreasing the sensitivity of OC cells to H2O2 | 43 |
ANKRD1, ankyrin repeat domain 1; ARID1A, SWI/SNF component; AGTR1, Angiotensin II receptor; CARM1, type I protein arginine methyltransferase; GRP78, 78 kDa glucose-regulated protein; HDAC6, histone deacetylase 6; HGSOC, high grade serous ovarian cancer; OC, ovarian cancer; OCCC, ovarian clear cell carcinomas; PDI, protein disulfide isomerase; PHLDA1, pleckstrin homology-like domain family A member 1; ROR2, receptor tyrosine kinase-like orphan receptors; TUSC3, tumor suppressor candidate 3; UCHL1, ubiquitin carboxyl-terminal hydrolase L1; WWOX, WW domain containing oxidoreductase; XBP1, X-box binding protein-1.